×

Biocept to Present at Upcoming Investor Conferences

SAN DIEGO, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) biomarker analysis, today announced that Michael Nall, Biocept President and CEO, will be presenting a corporate overview at the following upcoming investor conferences:

  • 16th Annual Rodman & Renshaw Global Investment Conference, being held September 8-10, 2014 at the New York Palace Hotel in New York, NY. The presentation will take place on Wednesday, September 10 at 2:55 PM ET. For those unable to attend, a live webcast of the presentation will be available in the Investors Relations; Events and Presentations section of the Company's website at www.biocept.com. Following the presentation, this webcast will be archived for 90 days.
  • 2014 Aegis Capital Healthcare & Technology Conference, being held September 10-13, 2014 at the Wynn Hotel in Las Vegas. The presentation will take place on Friday, September 12 at 9:30 AM PT.

About Biocept, Inc.

Biocept, Inc., headquartered in San Diego, California, is a commercial-stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its proprietary technology platform to help improve individual patient treatment. Biocept has developed proprietary technology platforms for capture and analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) utilizing a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers its OncoCEE-BRTM test for breast cancer and plans to introduce tests for lung, colorectal, prostate and other solid tumors based on its proprietary technology platforms.

CONTACT: Investor Contact: The Ruth Group David Burke (646) 536-7009 dburke@theruthgroup.com Media Contact: The Ruth Group Melanie Sollid-Penton (646) 536-7023 msollid@theruthgroup.comSource:Biocept, Inc.